{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:17:24Z","timestamp":1794493044846,"version":"4.9.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Human papillomavirus (HPV) vaccination within a nonorganized setting creates a poor cost-effectiveness scenario. However, framed within an organized screening including primary HPV DNA testing with lengthening intervals may provide the best health value for invested money. To compare the effectiveness and cost-effectiveness of different cervical cancer (CC) prevention strategies, including current status and new proposed screening practices, to inform health decision-makers in Spain, a Markov model was developed to simulate the natural history of HPV and CC. Outcomes included cases averted, life expectancy, reduction in the lifetime risk of CC, life years saved, quality-adjusted life years (QALYs), net health benefits, lifetime costs, and incremental cost-effectiveness ratios. The willingness-to-pay threshold is defined at 20\u2009000\u20ac\/QALY. Both costs and health outcomes were discounted at an annual rate of 3%. A strategy of 5-year organized HPV testing has similar effectiveness, but higher efficiency than 3-year cytology. Screening alone and vaccination combined with cytology are dominated by vaccination followed by 5-year HPV testing with cytology triage (12\u2009214\u20ac\/QALY). The optimal age for both ending screening and switching age from cytology to HPV testing in older women is 5 years later for unvaccinated than for vaccinated women. Net health benefits decrease faster with diminishing vaccination coverage than screening coverage. Primary HPV DNA testing is more effective and cost-effective than current cytological screening. Vaccination uptake improvements and a gradual change toward an organized screening practice are critical components for achieving higher effectiveness and efficiency in the prevention of CC in Spain.<\/jats:p>","DOI":"10.1097\/cej.0000000000000202","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T10:22:09Z","timestamp":1442398929000},"page":"430-439","source":"Crossref","is-referenced-by-count":15,"title":["Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis"],"prefix":"10.1097","volume":"25","author":[{"given":"Leonidas","family":"Georgalis","sequence":"first","affiliation":[{"name":"Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology (ICO)-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"de Sanjos\u00e9","sequence":"additional","affiliation":[{"name":"Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology (ICO)-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona"},{"name":"Public Health and Epidemiology (CIBERESP)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Esnaola","sequence":"additional","affiliation":[{"name":"Centre for Research in Environmental Epidemiology (CREAL), Barcelona Biomedical Research Park (PRBB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Xavier","family":"Bosch","sequence":"additional","affiliation":[{"name":"Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology (ICO)-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Diaz","sequence":"additional","affiliation":[{"name":"Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology (ICO)-IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 3","key":"R1-20230905","doi-asserted-by":"crossref","first-page":"iii43","DOI":"10.1093\/annonc\/mdq085","article-title":"Cancer screening in Spain","volume":"21","author":"Ascunce","year":"2010","journal-title":"Ann Oncol"},{"key":"R2-20230905","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25211","article-title":"The health and economic effects of HPV DNA screening in The Netherlands","volume":"127","author":"Berkhof","year":"2010","journal-title":"Int J Cancer J Int Cancer"},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/LGT.0b013e3181d734bd","article-title":"Clinical management of abnormal cytology test results and costs associated with the prevention of cervical cancer in Spain","volume":"14","author":"Blade","year":"2010","journal-title":"J Low Genit Tract Dis"},{"key":"R4-20230905","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1016\/j.vaccine.2011.09.055","article-title":"The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands","volume":"29","author":"Bogaards","year":"2011","journal-title":"Vaccine"},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3802\/jgo.2012.23.4.282","article-title":"New insights into cervical cancer screening","volume":"23","author":"Boone","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"R6-20230905","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2012.94","article-title":"Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway","volume":"106","author":"Burger","year":"2012","journal-title":"Br J Cancer"},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18230","article-title":"The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds","volume":"18","author":"C Kitchener","year":"2014","journal-title":"Health Technol Assess"},{"key":"R9-20230905","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6602002","article-title":"The predicted effect of changes in cervical screening practice in the UK: results from a modelling study","volume":"91","author":"Canfell","year":"2004","journal-title":"Br J Cancer"},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jmv.23282","article-title":"Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study","volume":"84","author":"Castellsagu\u00e9","year":"2012","journal-title":"J Med Virol"},{"issue":"Suppl 5","key":"R11-20230905","doi-asserted-by":"crossref","first-page":"F117","DOI":"10.1016\/j.vaccine.2012.05.071","article-title":"Introduction of human papillomavirus DNA screening in the world: 15 years of experience","volume":"30","author":"Castle","year":"2012","journal-title":"Vaccine"},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.vaccine.2012.01.001","article-title":"Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening","volume":"30","author":"Coup\u00e9","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"R13-20230905","doi-asserted-by":"crossref","first-page":"F107","DOI":"10.1016\/j.vaccine.2012.05.088","article-title":"New technologies and procedures for cervical cancer screening","volume":"30","author":"Cuzick","year":"2012","journal-title":"Vaccine"},{"key":"R14-20230905","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1136\/bmj.e670","article-title":"Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model","volume":"344","author":"de Kok","year":"2012","journal-title":"BMJ"},{"key":"R17-20230905","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.ejca.2010.06.016","article-title":"Cost-effectiveness of human papillomavirus vaccination and screening in Spain","volume":"46","author":"Diaz","year":"2010","journal-title":"Eur J Cancer Oxf Engl"},{"key":"R22-20230905","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/1471-2407-14-574","article-title":"Protecting the underscreened women in developed countries: the value of HPV test","volume":"14","author":"Ib\u00e1\u00f1ez","year":"2014","journal-title":"BMC Cancer"},{"key":"R23-20230905","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0272989X07302128","article-title":"Abnormal outcomes following cervical cancer screening: event duration and health utility loss","volume":"27","author":"Insinga","year":"2007","journal-title":"Med Decis Making"},{"key":"R25-20230905","doi-asserted-by":"crossref","first-page":"e48426","DOI":"10.1371\/journal.pone.0048426","article-title":"Potential benefits of second-generation human papillomavirus vaccines","volume":"7","author":"Kiatpongsan","year":"2012","journal-title":"PloS One"},{"key":"R26-20230905","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/dji162","article-title":"Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy","volume":"97","author":"Kim","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"R27-20230905","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/j.1524-4733.2009.00519.x","article-title":"The use of QALYs in clinical and patient decision-making: issues and prospects","volume":"12","author":"Kind","year":"2009","journal-title":"Value Health"},{"key":"R28-20230905","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/1471-2458-12-872","article-title":"Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6\/11\/16\/18 vaccine in Canada","volume":"12","author":"Kohli","year":"2012","journal-title":"BMC Public Health"},{"key":"R29-20230905","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"issue":"Suppl 5","key":"R30-20230905","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction \u2013 the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"R31-20230905","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10198-003-0187-0","article-title":"Economic evaluation of human papillomavirus screening in Germany","volume":"4","author":"Mittendorf","year":"2003","journal-title":"Eur J Health Econ"},{"key":"R32-20230905","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","article-title":"Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis","volume":"151","author":"Myers","year":"2000","journal-title":"Am J Epidemiol"},{"key":"R34-20230905","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","article-title":"The cervical cancer epidemic that screening has prevented in the UK","volume":"364","author":"Peto","year":"2004","journal-title":"Lancet"},{"key":"R35-20230905","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/LGT.0b013e3181599c16","article-title":"Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain","volume":"12","author":"Puig-Tintor\u00e9","year":"2008","journal-title":"J Low Genit Tract Dis"},{"issue":"Suppl 5","key":"R37-20230905","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"R38-20230905","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.bjc.6601884","article-title":"An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme","volume":"91","author":"Sherlaw-Johnson","year":"2004","journal-title":"Br J Cancer"},{"key":"R39-20230905","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ejca.2011.03.006","article-title":"Cost-effectiveness of primary HPV screening for cervical cancer in Germany \u2013 a decision analysis","volume":"47","author":"Sroczynski","year":"2011","journal-title":"Eur J Cancer Oxf Engl"},{"key":"R40-20230905","first-page":"1","article-title":"Guidelines for the screening of cervical cancer in Spain, 2014","volume":"47","author":"Torn\u00e9 Blad\u00e9","year":"2014","journal-title":"Rev Esp Patol"},{"key":"R42-20230905","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1471-0528.2011.03228.x","article-title":"Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing","volume":"119","author":"Van Rosmalen","year":"2012","journal-title":"BJOG"},{"key":"R43-20230905","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/infdis\/jir281","article-title":"Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses","volume":"204","author":"Westra","year":"2011","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"R47-20230905","first-page":"S3\/122","article-title":"Chapter 14: HPV vaccine introduction in industrialized countries","volume":"24","author":"Wright","year":"2006","journal-title":"Vaccine"},{"key":"R48-20230905","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jnci\/94.3.193","article-title":"Cost-effectiveness of cervical cancer screening: comparison of screening policies","volume":"94","author":"Van den Akker-van Marle","year":"2002","journal-title":"J Natl Cancer Inst"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008469-201609000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:31:40Z","timestamp":1693956700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008469-201609000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000202","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}